Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States

Detalhes bibliográficos
Autor(a) principal: Biedenbach, Douglas J.
Data de Publicação: 2007
Outros Autores: Ross, James E., Fritsche, Thomas R., Sader, Helio S. [UNIFESP], Jones, Ronald N.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
dARK ID: ark:/48912/001300000ms76
DOI: 10.1128/JCM.02368-06
Texto Completo: http://dx.doi.org/10.1128/JCM.02368-06
http://repositorio.unifesp.br/handle/11600/29521
Resumo: Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and beta-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC,0 values (0.19 mu g/ml) than oxacillin-susceptible strains (0.125 mu g/ml). This potency was 8- to 16-fold greater than that for vancomycin. P-Hemolytic streptococci had MIC90 values ranging between <= 0.016 and 0.064 mu g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was > 98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. beta-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample.
id UFSP_7f92f1eb0f49cb09878c6910bf7a3527
oai_identifier_str oai:repositorio.unifesp.br/:11600/29521
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesDalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and beta-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC,0 values (0.19 mu g/ml) than oxacillin-susceptible strains (0.125 mu g/ml). This potency was 8- to 16-fold greater than that for vancomycin. P-Hemolytic streptococci had MIC90 values ranging between <= 0.016 and 0.064 mu g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was > 98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. beta-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample.JMI Labs, Beaver Kreek Ctr 345, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, São Paulo, BrazilWeb of ScienceAmer Soc MicrobiologyJMI LabsUniversidade Federal de São Paulo (UNIFESP)Tufts UnivBiedenbach, Douglas J.Ross, James E.Fritsche, Thomas R.Sader, Helio S. [UNIFESP]Jones, Ronald N.2016-01-24T12:41:54Z2016-01-24T12:41:54Z2007-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion998-1004application/pdfhttp://dx.doi.org/10.1128/JCM.02368-06Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 45, n. 3, p. 998-1004, 2007.10.1128/JCM.02368-06WOS000245071500045.pdf0095-1137http://repositorio.unifesp.br/handle/11600/29521WOS:000245071500045ark:/48912/001300000ms76engJournal of Clinical Microbiologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-31T05:04:15Zoai:repositorio.unifesp.br/:11600/29521Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-12-11T20:25:49.428825Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
title Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
spellingShingle Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Biedenbach, Douglas J.
Biedenbach, Douglas J.
title_short Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
title_full Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
title_fullStr Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
title_full_unstemmed Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
title_sort Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States
author Biedenbach, Douglas J.
author_facet Biedenbach, Douglas J.
Biedenbach, Douglas J.
Ross, James E.
Fritsche, Thomas R.
Sader, Helio S. [UNIFESP]
Jones, Ronald N.
Ross, James E.
Fritsche, Thomas R.
Sader, Helio S. [UNIFESP]
Jones, Ronald N.
author_role author
author2 Ross, James E.
Fritsche, Thomas R.
Sader, Helio S. [UNIFESP]
Jones, Ronald N.
author2_role author
author
author
author
dc.contributor.none.fl_str_mv JMI Labs
Universidade Federal de São Paulo (UNIFESP)
Tufts Univ
dc.contributor.author.fl_str_mv Biedenbach, Douglas J.
Ross, James E.
Fritsche, Thomas R.
Sader, Helio S. [UNIFESP]
Jones, Ronald N.
description Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and beta-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC,0 values (0.19 mu g/ml) than oxacillin-susceptible strains (0.125 mu g/ml). This potency was 8- to 16-fold greater than that for vancomycin. P-Hemolytic streptococci had MIC90 values ranging between <= 0.016 and 0.064 mu g/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was > 98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. beta-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample.
publishDate 2007
dc.date.none.fl_str_mv 2007-03-01
2016-01-24T12:41:54Z
2016-01-24T12:41:54Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1128/JCM.02368-06
Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 45, n. 3, p. 998-1004, 2007.
10.1128/JCM.02368-06
WOS000245071500045.pdf
0095-1137
http://repositorio.unifesp.br/handle/11600/29521
WOS:000245071500045
dc.identifier.dark.fl_str_mv ark:/48912/001300000ms76
url http://dx.doi.org/10.1128/JCM.02368-06
http://repositorio.unifesp.br/handle/11600/29521
identifier_str_mv Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 45, n. 3, p. 998-1004, 2007.
10.1128/JCM.02368-06
WOS000245071500045.pdf
0095-1137
WOS:000245071500045
ark:/48912/001300000ms76
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Journal of Clinical Microbiology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 998-1004
application/pdf
dc.publisher.none.fl_str_mv Amer Soc Microbiology
publisher.none.fl_str_mv Amer Soc Microbiology
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1822183934336696320
dc.identifier.doi.none.fl_str_mv 10.1128/JCM.02368-06